Comorbidity of erosive gastroesophageal reflux disease and irritable bowel syndrome. Clinical case

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Background: Currently, significant importance is attached to comorbidity in gastrointestinal diseases. Comorbidity of gastroesophageal reflux disease and irritable bowel syndrome is associated with the presence of common pathophysiological mechanisms and is associated with a decrease in the quality of life.

Description of the clinical case: The article considers a clinical case of overlap syndrome of gastroesophageal reflux disease with erosive esophagitis and irritable bowel syndrome in a 37-year-old patient, as well as the effectiveness of therapy using a proton pump inhibitor and a selective myotropic antispasmodic in this case.

Conclusion: The combination of a PPI (pantoprazole) and a selective myotropic antispasmodic (mebeverine hydrochloride) can be considered when choosing therapy in comorbid patients.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Irina Kozlova

Saratov State Medical University named after V.I. Razumovsky

Email: jdipisma@mail.ru
ORCID iD: 0000-0002-5056-4504
SPIN-код: 7995-5124
Scopus Author ID: 7102626490
ResearcherId: B-2802-2017
Ресей, Saratov

Tatyana Tikhonova

Saratov State Medical University named after V.I. Razumovsky

Хат алмасуға жауапты Автор.
Email: jdipisma@mail.ru
ORCID iD: 0000-0002-0981-1083
SPIN-код: 4101-1360
Scopus Author ID: 57339702600
ResearcherId: AAA-9469-2021

Associate Professor, Department of Therapy, Gastroenterology and Pulmonology

Ресей, Saratov

Әдебиет тізімі

  1. Лазебник Л.Б., Голованова Е.В., Волель Б.А. и др. Функциональные заболевания органов пищеварения. Синдромы перекреста. Клинические рекомендации Российского научного медицинского общества терапевтов и научного общества гастроэнтерологов России. Экспериментальная и клиническая гастроэнтерология. 2021;192(8):5–117. [Lazebnik L.B., Golovanova E.V., Volel B.A., et al. Russian Scientifi c Medical Society of Therapists; Scientifi c Society of Gastroenterologists of Russia. Functional diseases of the digestive system. Crossover syndromes. Clinical guidelines. Experimental and Clinical Gastroenterology. 2021;192(8):5–117. (In Russ.)]. https://dx.doi.org/10.31146/1682-8658-ecg-192-8-5-117
  2. Ивашкин В.Т., Трухманов А.С., Маев И.В. и др. Диагностика и лечение гастроэзофагеальной рефлюксной болезни (Рекомендации Российской гастроэнтерологической ассоциации, Российского научного медицинского общества терапевтов, Российского общества профилактики неинфекционных заболеваний, Научного сообщества по изучению микробиома человека). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024;34(5):111–135. [Ivashkin V.T., Trukhmanov A.S., Maev I.V., et al. Diagnosis and Treatment of Gastroesophageal Reflux Disease (Clinical Guidelines of the Russian Gastroenterological Association, Russian Scientific Medical Society of Internal Medicine, Russian Society for the Prevention of Noncommunicable Diseases, Scientific Сommunity for Human Microbiome Research). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(5):111–135. (In Russ.)]. https://dx.doi.org/10.22416/1382-4376-2024-34-5-111-135
  3. Шептулин А.А., Виноградская К.Э. Сочетание гастроэзофагеальной рефлюксной болезни и синдрома раздраженного кишечника: какие вопросы остаются нерешенными? Клиническая медицина. 2020;98(9–10):645–649. [Sheptulin A.A., Vinogradskaya K.E. Gastroesophageal refl ux disease and irritable bowel syndrome overlapping: unresolved issues. Klinicheskaya meditsina. 2020;98(9–10):645–649. (In Russ.)]. https://dx.doi.org/10.30629/0023-2149-2020-98-9-10-645-649
  4. Морозова Ю.Н., Погромов А.П., Мнацаканян М.Г. и др. Расстройства пищевода у больных синдромом раздраженного кишечника. Терапевтический архив. 2020;92(2):19–23. [Morozova Yu.N., Pogromov A.P., Mnatsakanyan M.G., et al. Esophageal disorders in patients with irritable bowel syndrome. Therapeutic Archive. 2020;92(2):19–23. (In Russ.)]. https://dx.doi.org/10.26442/00403660.2020.02.000483
  5. Funaki Y., Kaneko H., Kawamura Y., et al. Impact of Comorbid Irritable Bowel Syndrome on Treatment Outcome in Non-Erosive Reflux Disease on Long-Term Proton Pump Inhibitor in Japan. Digestion. 2017;96(1):39–45. https://dx.doi.org/10.1159/000477801
  6. Wu H., Li J., Li F., et al. Causal association of gastroesophageal reflux disease on irritable bowel syndrome: a two-sample Mendelian randomization study. Front Genet. 2024; 15: 1328327. https://dx.doi.org/10.3389/fgene.2024.1328327
  7. Nam S.Y., Ryu K.H., Park B.J. Irritable bowel syndrome is associated with gastroesophageal reflux symptom but not erosive esophagitis. J Neurogastroenterol Motil. 2013;19(4):521–31. https://dx.doi.org/10.5056/jnm.2013.19.4.521
  8. El-Salhy M., Gilja O.H., Hatlebakk J.G. Overlapping of irritable bowel syndrome with erosive esophagitis and the performance of Rome criteria in diagnosing IBS in a clinical setting. Mol Med Rep. 2019;20(1):787–794. https://dx.doi.org/10.3892/mmr.2019.10284
  9. Lee S.W., Chang C.S. Impact of Overlapping Functional Gastrointestinal Disorders on the Quality of Life in Patients With Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2021;27(2):176–184. https://dx.doi.org/10.5056/jnm19006
  10. Martinucci I., Natilli M., Lorenzoni V., et al. Gastroesophageal reflux symptoms among Italian university students: epidemiology and dietary correlates using automatically recorded transactions. BMC Gastroenterol. 2018;18(1):116. https://dx.doi.org/10.1186/s12876-018-0832-9
  11. de Bortoli N., Tolone S., Frazzoni M., et al. Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. Ann Gastroenterol. 2018;31(6):639–648. https://dx.doi.org/10.20524/aog.2018.0314
  12. Nagasako K.C., Montes G.C., Lorena S., et al. Irritable bowel syndrome subtypes: Clinical and psychological features, body mass index and comorbidities. Rev Esp Enferm Dig. 2016;108(2):59–64. https://dx.doi.org/10.17235/reed.2015.3979/2015
  13. Alshammari S.A., Almutairi M.N., Alomar M.O., et al. Overlap Between Gastroesophageal Reflux Disease and Irritable Bowel Syndrome and Its Impact on Quality of Life. Cureus. 2023;15(12):e50840. https://dx.doi.org/10.7759/cureus.50840
  14. Loosen S.H., Kostev K., Jördens M.S., et al. Overlap between irritable bowel syndrome and common gastrointestinal diagnoses: a retrospective cohort study of 29,553 outpatients in Germany. BMC Gastroenterol. 2022;22(1):48. https://dx.doi.org/10.1186/s12876-022-02118-y
  15. Jones M.P., Shah A., Walker M.M., et al. Overlap of heartburn, functional dyspepsia, and irritable bowel syndrome in a population sample: Prevalence, temporal stability, and associated comorbidities. Neurogastroenterol Motil. 2022; 34(9):e14349. https://dx.doi.org/10.1111/nmo.14349
  16. Mönnikes H., Schwan T, van Rensburg C., et al. Randomised clinical trial: sustained response to PPI treatment of symptoms resembling functional dyspepsia and irritable bowel syndrome in patients suffering from an overlap with erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2012;35(11):1279–89.
  17. Шептулин А.А., Кардашева С.С., Курбатова А.А. Современные возможности применения пантопразола для лечения и профилактики гастроэнтерологических заболеваний. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(1):47–53. [Sheptulin A.A., Kardasheva S.S., Kurbatova A.A. Current Potential of Pantoprazole in Treatment and Prevention of Gastrointestinal Diseases. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(1):47–53. (In Russ.)]. https://dx.doi.org/10.1111/j.1365-2036.2012.05085.x
  18. Upadhyay R., Soni N.K., Kotamkar A.A., et al. High Dose Pantoprazole for Gastroesophageal Reflux Disease: Need, Evidence, Guidelines and Our Experience. Euroasian J Hepatogastroenterol. 2024;14(1):86–91. https://dx.doi.org/10.5005/jp-journals-10018-1426
  19. Wu J.C., Lai L.H., Chow D.K., et al. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease. Neurogastroenterol Motil. 2011;23(2):155–60,e31. https://dx.doi.org/10.1111/j.1365-2982.2010.01627.x
  20. Бутов М.А., Мсакни М., Бутова В.М., Судакова Н.А., Ворначёва И.Ю., Карпова Л.И. Влияние мебеверина в капсулах пролонгированного высвобождения на моторную функцию кишечника у больных с функциональной гастроинтестинальной патологией. Медицинский алфавит. 2024;(5):7–12. [Butov M.A., Msakni M., Butova V.M., et al. The effect of mebeverine in extended-release capsules on intestinal motor function in patients with functional gastrointestinal pathology. Medical alphabet. 2024;(5):7–12. (In Russ.)]. https://dx.doi.org/10.33667/2078-5631-2024-5-7-12
  21. Daniluk J., Malecka-Wojciesko E., Skrzydlo-Radomanska B., et al. The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome-A Systematic Review. J Clin Med. 2022;11(4):1044. https://dx.doi.org/10.3390/jcm11041044

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2025